RT Journal Article
SR Electronic
T1 Capecitabine plus Hepatic Intra-arterial Epirubicin and Cisplatin in Unresectable Biliary Cancer: A Phase II Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3009
OP 3013
VO 27
IS 4C
A1 ANDREA MAMBRINI
A1 ALFREDO GUGLIELMI
A1 PAOLA PACETTI
A1 CALOGERO IACONO
A1 TITO TORRI
A1 ALESSIO AUCI
A1 NICOLA NICOLI
A1 MASSIMO ORLANDI
A1 STEFANO GUADAGNI
A1 GIAMMARIA FIORENTINI
A1 MAURIZIO CANTORE
YR 2007
UL http://ar.iiarjournals.org/content/27/4C/3009.abstract
AB The aim of the present study was to evaluate the activity of hepatic intra-arterial infusion of epirubicin and cisplatin combined with oral capecitabine, in patients with unresectable biliary carcinomas. Patients and Methods: Twenty patients were treated by bolus infusion of epirubicin 50 mg/m2 and cisplatin 60 mg/m2 in the hepatic artery on day 1, combined with oral capecitabine 1000 mg/m2 bid, from day 2 to day 15. Results: Partial responses (PR) were observed in 6 patients (31.5%), stable disease (SD) in 9 (47.5%) and progression (PD) in 4 (21%). The median progression-free and overall survival periods were 11.6 and 18.0 months, respectively, and 1-year survival was 74%. One patient died after the first cycle because of G4 diarrhea. The other patients had good tolerance, with minimal hematological toxicity and only 1 G3 vomiting. Conclusion: This combined intra-arterial and oral approach to patients with biliary carcinomas was found to be active and safe and seems to produce an encouraging survival response.